Association of synergistic effects of Wuzhi capsules on tacrolimus and PXR polymorphisms

Abstract

Abstract:

AIM: To investigate the association of synergistic effects of Wuzhi capsules on tacrolimus and PXR polymorphisms. METHODS: A total of 74 patients were continually administered with Wuzhi capsules for 24 months as Wuzhi capsules (+) group. A total of 96 patients took tacrolimus alone as Wuzhi capsules (－) group. The PXR 7635 A>G (rs6785049) and PXR 24381 A>C (rs1523127) genotypes were determined by PCR-direct sequencing. PXR 6bp deletions (rs3842689) genotype was determined by Allelic Special-Touch down PCR. The tacrolimus whole blood levels of renal transplant recipients were measured by chemiluminescent microparticle immunoassay.Analysis of covariance (ANCOVA) was performed to determine the difference of tacrolimus C0/D among various groups. RESULTS: Tacrolimus C0/D of patients with PXR 7635 A>G GG was significantly higher than that with GA/AA in Wuzhi capsules (+) group from 3 months to 24 months (P=0.005, 0.049, 0.001, 0.031, 0.035) and there was no significant difference in Wuzhi capsule (－) group. Whether co-administration of Wuzhi capsules and tacrolimus or not, PXR 6bp deletions, PXR 24381 A>C genotype were not associated with tacrolimus C0/D.CONCLUSION:When combined with Wuzhi capsules, PXR 7635 G>A mutation might associate with tacrolimus C0/D.

Key words: PXR, genic polymorphism, Wuzhi capsules, tacrolimus, renal transplantation

CLC Number:

R968

XIN Huawen, YANG Yan. Association of synergistic effects of Wuzhi capsules on tacrolimus and PXR polymorphisms[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(10): 1138-1144.

References

［1］中华医学会器官移植学分会. 他克莫司在临床肝移植中的应用指南［J］. 临床肝胆病杂志，2015, 31(9): 1372-1374.
［2］Knops N, Levtchenko E, van den Heuvel B, et al. From gut to kidney: Transporting and metabolizing calcineurin-inhibitors in solid organ transplantation［J］. Int J Pharmaceut, 2013, 452(1/2): 14-35.
［3］Cerveny L, Svecova L, Anzenbacherova E, et al. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways［J］. Drug Metab Dispos, 2007, 35(7): 1032-1041.
［4］Burk O, Koch I, Raucy J, et al. The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR) ［J］. J Biol Chem, 2004, 279(37): 38379-38385.
［5］Albermann N, Schmitz-Winnenthal FH, Z'Graggen K, et al. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver ［J］. Biochem Pharmacol, 2005, 70(6): 949-958.
［6］Press R, Ploeger B, Hartigh JD, et al. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients［J］. Ther Drug Monit, 2009, 31(2): 187-197.
［7］王金平，李澎灏，李雯, 等. 基于孕烷X受体基因多态性指导肾移植受者他克莫司的个体化用药［J］. 中国药房, 2013, 24(22): 2049-2050.
［8］Liu Y, Ji W, Yin Y, et al. The effects of splicing variant of PXR PAR-2 on CYP3A4and MDR1 mRNA expressions ［J］. Clin Chim Acta, 2009, 403(1/2): 142-144.
［9］Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux ［J］. Nat Med, 2001, 7(5): 584-590.
［10］Xin HW, Wu XC, Li Q, et al. Effects of schisandra sphenanthera extract on the pharmaco kinetics of tacrolimus in healthy volunteers ［J］. Br J Clin Pharmacol, 2007, 64(4): 469-475.
［11］Xin HW, Wu XC, Li Q, et al. Effects of schisandra sphenanthera extract on the pharmacokinetics of midazolam in healthy volunteers ［J］. Br J Clin Pharmacol, 2009, 67(5): 541-546.
［12］Xin HW, Li Q, Wu XC,et al. Effects of schisandra sphenanthera extract on the blood concentration of tacrolimus in renal transplant recipients［J］. Eur J Clin Pharmacol, 2011, 67(12): 1309-1311.
［13］何海雁, 张叶, 刘宏明. HPLC法同时测定五酯胶囊中五味子醇甲、五味子酯甲、五味子甲素和五味子乙素的含量［J］. 药学研究, 2015, 34(11): 642-644.
［14］Qin XL, Bi HC, Wang XD,et al. Mechanistic understanding of the different effects of wuzhi tablet (schisandra sphenanthera extract) on the absorption and first-pass intestinal and hepatic metabolism of tacrolimus (FK506)［J］. Int J Pharmaceut, 2010, 389(1/2): 114-121.
［15］Zeng H, Li D, Qin X, et al. Hepatoprotective effects of schisandra sphenanthera extract against lithocholic acid-induced cholestasis in male mice are associated with activation of the pregnane X receptor pathway and promotion of liver regeneration［J］. Drug Metab Dispos, 2016, 44(3): 337-342.
［16］郭志华. PXR和VKORC1基因多态性对华法林维持剂量的影响［D］. 湖南，中南大学硕士学位论文, 2010.
［17］李澎灏, 王金平, 李雯, 等. 孕烷X受体基因多态性对肾移植受者他克莫司浓度/剂量比的影响［J］. 中国临床药理学杂志, 2013,29(6): 446-448.
［18］Zahir H, McCaughan G, Gleeson M, et al. Factors affecting variability in distribution of tacrolimus in liver transplant recipients［J］. Br J Clin Pharmacol, 2003, 57(3): 298-309.
［19］陈倩. 五味子对大鼠肝CYP3A酶抑制和诱导双重作用机制的探讨［D］. 上海, 复旦大学硕士学位论文, 2009.

[1]	LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao. Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774.
[2]	WANG Shuang, LIU jia, ZHANG Yueli. Associations of POR*28 polymorphisms with tacrolimus stable dose in Chinese kidney transplantation patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 991-997.
[3]	DU Wenpeng, AO Jiangen, TAO Yi, WU Guansheng, HE Jiake. Study on the factors affecting the steady-state blood concentration of tacrolimus in patients with autoimmune diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 645-651.
[4]	WU Yi, FANG Fang, CHEN Ying, Fan Junwei. Influence of donor and recipient CYP3A5 genotype on tacrolimus trough concentrations in the early stage after liver transplantation and its clinical significance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 631-639.
[5]	WU Yi, WANG Rangrang, WANG Zhaowen, FAN Junwei. Effect of recipient SLCO1B1 rs2291075 polymorphism on tacrolimus dose-corrected trough concentration in early postoperative period of liver transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(11): 1268-1275.
[6]	YAN Wenlong, SHU shuhua, LI Juan. Effects of tight control of metabolic acidosis with 5% sodium bicarbonate on early renal function after living donor renal transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(10): 1139-1144.
[7]	FANG Xi, QU Qiang, XIAO Xiangcheng. Advances in the treatment of tacrolimus in idiopathic membranous nephropathy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(2): 228-234.
[8]	LI Dong-liang, LI Bing, ZHANG Zhi-qiang, WANG Xiao, FANG Jian, ZHANG Shi-an, CAI Li-rong. Effects of two types of schisandra preparations on the plasma concentrations of immunosuppressant tacrolimus in rats and protective effect of liver injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(3): 256-260.
[9]	TANG Xia, XIN Hua-wen, LI Wei-liang, OUYANG Meng. Study of the effects of Berberine on CYP3A4 and P-gp in HepG2 cells and its mechanism in vitro [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(1): 7-13.
[10]	ZHANG Yue-li, MING Ying-zi, ZHOU Hong-hao, ZHANG Wei. Tacrolimus pathways:pharmacokinetics,pharmacodynamics and pharmacogenomics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(9): 1042-1049.
[11]	PENG Jian-yun, XU Wei-hai, ZHANG Xiao-ru, LAN Le-jian, GUI Zhi-hong, XIANG Mei-juan. Small dose of tacrolimus combined with hormone in the treatment of refractory nephrotic syndrome [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(2): 196-199.
[12]	WANG Jiang-lin, ZUO Xiao-cong, YANG Meng, ZHOU Ling-yun. Advances in the study of post-transplantation diabetes mellitus resulting from tacrolimus via calcineurin/NFAT signaling [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(1): 74-81.
[13]	YANG Meng, ZUO Xiao-cong,WANG Jiang-lin,CHEN Qing-Jie. Advance in study on tacrolimus pharmacodynamics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(1): 90-95.
[14]	CHEN Qun, XU Zhe, SUN Hua, XIE Hai-tang. Advances on biological characteristics of PXR and its effect on drug metabolism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(3): 241-246.
[15]	WEI Bing-hua, YE Yi-fang, LUO Mei-juan, HONG Xiao-dan, LI Bi-hong, RONG Ying-ci, REN Bin. Study on individual administration of tacrolimus in liver transplantation recipients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(7): 791-796.